Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 6Breast 3Lymphoid 2Endocrine 2Tumor-Agnostic 1Other hematologic neoplasm 1Other 1Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Lansoprazole × Breast × Clear all
NCT04188119 2025-12-08

IMpALA

The Christie NHS Foundation Trust

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT04874935 2022-11-15

The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer

Tanta University

Phase 3 Completed
66 enrolled
Breast

Breast Neoplasms

NCT03794596 2019-07-22

IMpALA

The Christie NHS Foundation Trust

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡